Vitura Health Limited
Vitura Health Limited (VIT.AX) Stock Competitors & Peer Comparison
See (VIT.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VIT.AX | A$0.07 | -1.37% | 47M | 7.10 | A$0.01 | N/A |
| CAU.AX | A$0.54 | +0.00% | 300.5M | -16.88 | -A$0.03 | N/A |
| AFP.AX | A$2.40 | +0.00% | 251.7M | 24.00 | A$0.10 | +0.43% |
| PBP.AX | A$2.98 | -0.33% | 242.3M | 29.80 | A$0.10 | N/A |
| LV1.AX | A$0.92 | +0.00% | 144.1M | 3.05 | A$0.30 | N/A |
| VLS.AX | A$2.21 | -2.21% | 122.8M | 14.12 | A$0.16 | +4.42% |
| IHL.AX | A$0.04 | -10.87% | 65.1M | -0.03 | -A$1.30 | N/A |
| MVP.AX | A$0.65 | +16.22% | 64.2M | -1.68 | -A$0.34 | N/A |
| ANP.AX | A$0.06 | -4.92% | 52.3M | -2.90 | -A$0.02 | N/A |
| NXS.AX | A$0.14 | -3.45% | 42.4M | -2.42 | -A$0.06 | N/A |
Stock Comparison
VIT.AX vs CAU.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, CAU.AX has a market cap of 300.5M. Regarding current trading prices, VIT.AX is priced at A$0.07, while CAU.AX trades at A$0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas CAU.AX's P/E ratio is -16.88. In terms of profitability, VIT.AX's ROE is +0.05%, compared to CAU.AX's ROE of +0.34%. Regarding short-term risk, VIT.AX is less volatile compared to CAU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check CAU.AX's competition here
VIT.AX vs AFP.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, AFP.AX has a market cap of 251.7M. Regarding current trading prices, VIT.AX is priced at A$0.07, while AFP.AX trades at A$2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas AFP.AX's P/E ratio is 24.00. In terms of profitability, VIT.AX's ROE is +0.05%, compared to AFP.AX's ROE of +0.13%. Regarding short-term risk, VIT.AX is more volatile compared to AFP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check AFP.AX's competition here
VIT.AX vs PBP.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, PBP.AX has a market cap of 242.3M. Regarding current trading prices, VIT.AX is priced at A$0.07, while PBP.AX trades at A$2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas PBP.AX's P/E ratio is 29.80. In terms of profitability, VIT.AX's ROE is +0.05%, compared to PBP.AX's ROE of +0.13%. Regarding short-term risk, VIT.AX is more volatile compared to PBP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check PBP.AX's competition here
VIT.AX vs LV1.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, LV1.AX has a market cap of 144.1M. Regarding current trading prices, VIT.AX is priced at A$0.07, while LV1.AX trades at A$0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas LV1.AX's P/E ratio is 3.05. In terms of profitability, VIT.AX's ROE is +0.05%, compared to LV1.AX's ROE of -4.96%. Regarding short-term risk, VIT.AX is more volatile compared to LV1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check LV1.AX's competition here
VIT.AX vs VLS.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, VLS.AX has a market cap of 122.8M. Regarding current trading prices, VIT.AX is priced at A$0.07, while VLS.AX trades at A$2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas VLS.AX's P/E ratio is 14.12. In terms of profitability, VIT.AX's ROE is +0.05%, compared to VLS.AX's ROE of +0.17%. Regarding short-term risk, VIT.AX is more volatile compared to VLS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check VLS.AX's competition here
VIT.AX vs IHL.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, IHL.AX has a market cap of 65.1M. Regarding current trading prices, VIT.AX is priced at A$0.07, while IHL.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas IHL.AX's P/E ratio is -0.03. In terms of profitability, VIT.AX's ROE is +0.05%, compared to IHL.AX's ROE of -0.33%. Regarding short-term risk, VIT.AX is less volatile compared to IHL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check IHL.AX's competition here
VIT.AX vs MVP.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, MVP.AX has a market cap of 64.2M. Regarding current trading prices, VIT.AX is priced at A$0.07, while MVP.AX trades at A$0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas MVP.AX's P/E ratio is -1.68. In terms of profitability, VIT.AX's ROE is +0.05%, compared to MVP.AX's ROE of -0.59%. Regarding short-term risk, VIT.AX is less volatile compared to MVP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check MVP.AX's competition here
VIT.AX vs ANP.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, ANP.AX has a market cap of 52.3M. Regarding current trading prices, VIT.AX is priced at A$0.07, while ANP.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas ANP.AX's P/E ratio is -2.90. In terms of profitability, VIT.AX's ROE is +0.05%, compared to ANP.AX's ROE of -0.73%. Regarding short-term risk, VIT.AX is less volatile compared to ANP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check ANP.AX's competition here
VIT.AX vs NXS.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, NXS.AX has a market cap of 42.4M. Regarding current trading prices, VIT.AX is priced at A$0.07, while NXS.AX trades at A$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas NXS.AX's P/E ratio is -2.42. In terms of profitability, VIT.AX's ROE is +0.05%, compared to NXS.AX's ROE of -2.01%. Regarding short-term risk, VIT.AX is more volatile compared to NXS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check NXS.AX's competition here
VIT.AX vs IDT.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, IDT.AX has a market cap of 37.9M. Regarding current trading prices, VIT.AX is priced at A$0.07, while IDT.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas IDT.AX's P/E ratio is -9.00. In terms of profitability, VIT.AX's ROE is +0.05%, compared to IDT.AX's ROE of -0.19%. Regarding short-term risk, VIT.AX is more volatile compared to IDT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check IDT.AX's competition here
VIT.AX vs LGP.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, LGP.AX has a market cap of 35.1M. Regarding current trading prices, VIT.AX is priced at A$0.07, while LGP.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas LGP.AX's P/E ratio is 11.50. In terms of profitability, VIT.AX's ROE is +0.05%, compared to LGP.AX's ROE of -0.12%. Regarding short-term risk, VIT.AX is more volatile compared to LGP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check LGP.AX's competition here
VIT.AX vs CPH.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, CPH.AX has a market cap of 23.1M. Regarding current trading prices, VIT.AX is priced at A$0.07, while CPH.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas CPH.AX's P/E ratio is -0.45. In terms of profitability, VIT.AX's ROE is +0.05%, compared to CPH.AX's ROE of -1.31%. Regarding short-term risk, VIT.AX is more volatile compared to CPH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check CPH.AX's competition here
VIT.AX vs AGH.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, AGH.AX has a market cap of 20.3M. Regarding current trading prices, VIT.AX is priced at A$0.07, while AGH.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas AGH.AX's P/E ratio is -0.60. In terms of profitability, VIT.AX's ROE is +0.05%, compared to AGH.AX's ROE of -51.14%. Regarding short-term risk, VIT.AX is less volatile compared to AGH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check AGH.AX's competition here
VIT.AX vs PXS.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, PXS.AX has a market cap of 20.2M. Regarding current trading prices, VIT.AX is priced at A$0.07, while PXS.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas PXS.AX's P/E ratio is -1.40. In terms of profitability, VIT.AX's ROE is +0.05%, compared to PXS.AX's ROE of -1.12%. Regarding short-term risk, VIT.AX is more volatile compared to PXS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check PXS.AX's competition here
VIT.AX vs MXC.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, MXC.AX has a market cap of 18.4M. Regarding current trading prices, VIT.AX is priced at A$0.07, while MXC.AX trades at A$0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas MXC.AX's P/E ratio is -0.13. In terms of profitability, VIT.AX's ROE is +0.05%, compared to MXC.AX's ROE of +26.60%. Regarding short-term risk, VIT.AX is less volatile compared to MXC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check MXC.AX's competition here
VIT.AX vs AC8.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, AC8.AX has a market cap of 17.6M. Regarding current trading prices, VIT.AX is priced at A$0.07, while AC8.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas AC8.AX's P/E ratio is -0.67. In terms of profitability, VIT.AX's ROE is +0.05%, compared to AC8.AX's ROE of -0.61%. Regarding short-term risk, VIT.AX is more volatile compared to AC8.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check AC8.AX's competition here
VIT.AX vs ECS.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, ECS.AX has a market cap of 10.4M. Regarding current trading prices, VIT.AX is priced at A$0.07, while ECS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas ECS.AX's P/E ratio is N/A. In terms of profitability, VIT.AX's ROE is +0.05%, compared to ECS.AX's ROE of -0.05%. Regarding short-term risk, VIT.AX is more volatile compared to ECS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check ECS.AX's competition here
VIT.AX vs HGV.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, HGV.AX has a market cap of 10.1M. Regarding current trading prices, VIT.AX is priced at A$0.07, while HGV.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas HGV.AX's P/E ratio is -2.40. In terms of profitability, VIT.AX's ROE is +0.05%, compared to HGV.AX's ROE of -0.01%. Regarding short-term risk, VIT.AX is more volatile compared to HGV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check HGV.AX's competition here
VIT.AX vs PER.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, PER.AX has a market cap of 9.8M. Regarding current trading prices, VIT.AX is priced at A$0.07, while PER.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas PER.AX's P/E ratio is -0.45. In terms of profitability, VIT.AX's ROE is +0.05%, compared to PER.AX's ROE of -1.23%. Regarding short-term risk, VIT.AX is less volatile compared to PER.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check PER.AX's competition here
VIT.AX vs CAN.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, CAN.AX has a market cap of 9.8M. Regarding current trading prices, VIT.AX is priced at A$0.07, while CAN.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas CAN.AX's P/E ratio is -0.15. In terms of profitability, VIT.AX's ROE is +0.05%, compared to CAN.AX's ROE of -4.70%. Regarding short-term risk, VIT.AX is less volatile compared to CAN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check CAN.AX's competition here
VIT.AX vs IVX.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, IVX.AX has a market cap of 8.5M. Regarding current trading prices, VIT.AX is priced at A$0.07, while IVX.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas IVX.AX's P/E ratio is -0.90. In terms of profitability, VIT.AX's ROE is +0.05%, compared to IVX.AX's ROE of -0.49%. Regarding short-term risk, VIT.AX is more volatile compared to IVX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check IVX.AX's competition here
VIT.AX vs EOF.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, EOF.AX has a market cap of 7.3M. Regarding current trading prices, VIT.AX is priced at A$0.07, while EOF.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas EOF.AX's P/E ratio is -0.50. In terms of profitability, VIT.AX's ROE is +0.05%, compared to EOF.AX's ROE of -0.51%. Regarding short-term risk, VIT.AX is less volatile compared to EOF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check EOF.AX's competition here
VIT.AX vs EPN.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, EPN.AX has a market cap of 7.2M. Regarding current trading prices, VIT.AX is priced at A$0.07, while EPN.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas EPN.AX's P/E ratio is -2.40. In terms of profitability, VIT.AX's ROE is +0.05%, compared to EPN.AX's ROE of -0.13%. Regarding short-term risk, VIT.AX is less volatile compared to EPN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check EPN.AX's competition here
VIT.AX vs CGB.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, CGB.AX has a market cap of 5.6M. Regarding current trading prices, VIT.AX is priced at A$0.07, while CGB.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas CGB.AX's P/E ratio is -0.70. In terms of profitability, VIT.AX's ROE is +0.05%, compared to CGB.AX's ROE of +0.00%. Regarding short-term risk, VIT.AX is more volatile compared to CGB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check CGB.AX's competition here
VIT.AX vs EXL.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, EXL.AX has a market cap of 4.6M. Regarding current trading prices, VIT.AX is priced at A$0.07, while EXL.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas EXL.AX's P/E ratio is -1.70. In terms of profitability, VIT.AX's ROE is +0.05%, compared to EXL.AX's ROE of -0.20%. Regarding short-term risk, VIT.AX is less volatile compared to EXL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check EXL.AX's competition here
VIT.AX vs BOD.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, BOD.AX has a market cap of 4.3M. Regarding current trading prices, VIT.AX is priced at A$0.07, while BOD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas BOD.AX's P/E ratio is -0.40. In terms of profitability, VIT.AX's ROE is +0.05%, compared to BOD.AX's ROE of +0.66%. Regarding short-term risk, VIT.AX is less volatile compared to BOD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check BOD.AX's competition here
VIT.AX vs SCU.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, SCU.AX has a market cap of 3.9M. Regarding current trading prices, VIT.AX is priced at A$0.07, while SCU.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas SCU.AX's P/E ratio is N/A. In terms of profitability, VIT.AX's ROE is +0.05%, compared to SCU.AX's ROE of -0.66%. Regarding short-term risk, VIT.AX is less volatile compared to SCU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VIT.AX.Check SCU.AX's competition here
VIT.AX vs TSN.AX Comparison August 2025
VIT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIT.AX stands at 47M. In comparison, TSN.AX has a market cap of 1.4M. Regarding current trading prices, VIT.AX is priced at A$0.07, while TSN.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIT.AX currently has a P/E ratio of 7.10, whereas TSN.AX's P/E ratio is -0.33. In terms of profitability, VIT.AX's ROE is +0.05%, compared to TSN.AX's ROE of -0.97%. Regarding short-term risk, VIT.AX is more volatile compared to TSN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for VIT.AX.Check TSN.AX's competition here